Brief: Sprint Bioscience Q4 Operating Loss Widens To SEK 10.8 Mln
20/02/2019 07:40
Feb 20 (Reuters) - Sprint Bioscience AB SPRINT.ST :
* Q4 OPERATING RESULTS AT -10,8 (-7,2) MSEK
* Q4 NET INCOME AT 0,2 (2,9) MSEK
Source text for Eikon: ID:nWkr79sv4J
Further company coverage: SPRINT.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln